glp-1 pediatric obesity Weighing up the options: childhood intervention to tackle Experts caution against turning to
Description
These combined effects make GLP-1 receptor agonists particularly valuable for patients with type 2 diabetes who are overweight or obese
TAM, tumor-associated macrophage
Semaglutide has been in clinical use since 2017
Torrent Pharmaceuticals Ltd
A separate analysis across multiple trials noted modest average weight changes in the range of approximately four to five pounds, with the important caveat that trials varied significantly in dose, duration, and population
The question is whether we can harness it reliably and predictably through commercial products
